BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/25/2021 2:11:51 AM | Browse: 446 | Download: 700
 |
Received |
|
2021-03-31 13:45 |
|
Peer-Review Started |
|
2021-03-31 14:09 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-06-23 06:35 |
|
Revised |
|
2021-06-28 03:38 |
|
Second Decision |
|
2021-08-03 03:29 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-08-03 08:21 |
|
Articles in Press |
|
2021-08-03 08:21 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-08-23 10:33 |
|
Publish the Manuscript Online |
|
2021-08-25 02:11 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Immune checkpoint inhibitor-related hepatotoxicity: A review
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Devika Remash, David S Prince, Catriona McKenzie, Simone I Strasser, Steven Kao and Ken Liu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ken Liu, BSc, FRACP, MBBS, Consultant Physician-Scientist, Senior Lecturer, Staff Physician, AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Missenden Road, Camperdown, Sydney 2050, NSW, Australia. ken.liu@health.nsw.gov.au |
| Key Words |
Immunotherapy; Immune checkpoint inhibitors; Hepatitis; Adverse drug event; Drug-induced liver injury; Immunosuppression |
| Core Tip |
Immune checkpoint inhibitor (ICI)-related hepatotoxicity (ICH) is an increasingly encountered clinical problem for gastroenterologists. Although the diagnosis should be suspected in patients receiving ICI with liver function test derangements, a thorough history, examination and targeted liver investigations including cross-sectional imaging should be performed to exclude differential diagnoses. Once ICH is confirmed, its severity should be graded which then guides management. Management of ICH follows a stepwise approach beginning with cessation of ICI, followed by corticosteroids and other immunosuppressants with close monitoring after each step. The decision to recommence ICI after recovery is made on a case-by-case basis. |
| Publish Date |
2021-08-25 02:11 |
| Citation |
Remash D, Prince DS, McKenzie C, Strasser SI, Kao S, Liu K. Immune checkpoint inhibitor-related hepatotoxicity: A review. World J Gastroenterol 2021; 27(32): 5376-5391 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i32/5376.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i32.5376 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
